DUBLIN--(BUSINESS WIRE)--The "Investigation Report on Chinese Latanoprost Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
Latanoprost is the first FDA approved prostaglandin for intraocular pressure reduction. In 1999, China began importing Latanoprost as a first-line drug in the clinical treatment of glaucoma. In 2004, Latanoprost eye drops developed by Lunan Better were approved for sale, followed by the products of other domestic manufacturers. And there is a continuous rise in the market share of domestic manufacturers. In 2017, Pfizer had the largest market share by sales value, about 39%, a figure that has been declining in recent years.
According to the report, Latanoprost has been growing since it entered China, with its sales value exceeding CNY 40 million in 2017. With an aging population, the incidence of glaucoma is increasing year by year in China. In clinical practice, glaucoma cannot be well treated through operations as cataracts. Therefore, there is a promising market for conservative medications and post-operative medications, and thus a high demand for Latanoprost in China.
Key Topics Covered:
1 Basic Concepts of Latanoprost
1.1 Indications for Latanoprost
1.2 Development History of Latanoprost in China
1.3 Governmental Approval of Latanoprost in China
2 Investigation on Sales of Latanoprost in China, 2013-2017
2.1 Sales Value of Latanoprost in China
2.2 Sales Value of Latanoprost in China
2.3 Sales of Latanoprost in China by Dosage Form
3 Major Latanoprost Manufacturers in China
3.1 Market Competition of Latanoprost in China
3.4 Lunan Better Pharmaceutical Co., Ltd.
3.5 China Resources Zizhu Pharmaceutical Co., Ltd.
3.6 Taejoon Pharm
3.7 Chengdu Hengrui Pharmaceutical Co., Ltd.
4 Analysis of Prices of Latanoprost in China, 2017-2018
4.1 Prices of Latanoprost in China
4.2 Prices of Major Manufacturers' Latanoprost in China
5 Prospects of Chinese Latanoprost Market, 2018-2022
5.1 Factors Influencing Latanoprost Development in China
5.2 Forecast on Market Size
5.3 Forecast on Competition Pattern
- Chengdu Hengrui Pharmaceutical Co., Ltd.
- China Resources Zizhu Pharmaceutical Co., Ltd.
- Lunan Better Pharmaceutical Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/p5n3ss/investigation?w=4